BAUM CHARLES M 4

What Happened Charles M. Baum, a director of Acrivon Therapeutics, was granted a derivative award of 20,275 shares on 2026-06-17. The award is reported at a $0.00 price (no cash paid) and is recorded as a grant/award (derivative security). The filing shows total value attributed to the acquisition as $0.

Key Details

• Transaction date: 2026-06-17; Form 4 filed: 2026-06-22 (appears to be filed after the 2-business-day deadline).
• Security: Derivative award of 20,275 shares; reported acquisition price $0.00.
• Shares owned after transaction: Not disclosed in the provided filing.
• Footnote: The shares subject to the award will vest on the date immediately preceding the issuer's next annual meeting of stockholders, subject to Baum’s continuous service through the vesting date.
• Transaction code: A = Award/Grant (derivative).

Context This was a grant of a derivative award (not an open-market purchase or sale). Such awards are commonly used for director compensation and vest over time; they do not by themselves indicate immediate buying or selling activity. The filing date is five days after the transaction date, which appears late relative to the typical 2-business-day Form 4 reporting requirement.